Clinical Trial Update: Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a combination of alvocidib, fludarabine phosphate, and rituximab in various B-cell lymphoproliferative disorders, with the trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Hairy Cell Leukemia
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Mucosa-associated Lymphoid Tissue Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Alvocidib (Flavopiridol)
• Fludarabine phosphate (Fludarabine phosphate)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Grade 1 Follicular Lymphoma | Phase 1 | Status: COMPLETED